Effect of electrospraying conditions on the properties of aspalathin‐Eudragit S100 nanoparticles and assessment of orogastrointestinal stability and membrane permeability

Human, Chantelle; Beer, Dalene de; Bowles, Sandra; Joubert, Elizabeth

doi:10.1002/fft2.131

Cited by 3 publications

(1 citation statement)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Optimization of Prescription by Central Composite Design Method. The amount of organic solvent(acetone) and the ratio of drug amount to excipient amount were selected as two conditions for prescription optimization using the central composite design response surface method (CCD design method) [19][20][21] using Design Expert 12 software [22].…”

Section: Single-factor Testmentioning

confidence: 99%

Study on Central Composite Design Method to Optimize the Preparation Process of Chrysophanol-Pluronic F127 Nanomicelles and Pharmacokinetics

Wang

Qiao³

et al. 2022

Journal of Nanomaterials

View full text Add to dashboard Cite

Objective. In order to find the best process for the preparation of Chrysophanol-Pluronic F127 nanomicelles in the laboratory, the preparation of Chrysophanol-Pluronic F127 nanomicelles was optimized using the central composite design method. In order to investigate the properties of the prepared Chrysophanol-Pluronic F127 nanomicelles, physicochemical properties were examined and in vitro dissolution experiments were performed, and the pharmacokinetics of Chrysophanol and Chrysophanol-Pluronic F127 nanomicelles were investigated in rabbits. Methods. In the preexperimental study, the best physical solubilization method and organic solvent for Chrysophanol were selected. The ratio of drug dosage to excipient dosage and the amount of organic solvents were evaluated by single-factor test. Based on the single-factor test, the optimal prescription was obtained by screening the formulation and optimizing the preparation process using the central composite design method with the encapsulation efficiency as the index. Chrysophanol-Pluronic F127 nanomicelles were prepared according to the optimal prescription, and their particle size, potential, appearance, and in vitro release experiments were carried out. Chrysophanol and Chrysophanol-Pluronic F127 nanomicelles were injected intravenously through the ear margins to rabbits, and the drug concentrations in the blood were measured at different time points by HPLC. The obtained blood concentration data were fitted with PK Solver 2.0 program to obtain pharmacokinetic parameters. Results. In the preexperimental study, ultrasonic method was selected as the physical solubilization method, and acetone was selected as the organic solvent. In single-factor test, the highest encapsulation efficiency was achieved when the ratio of drug dosage to excipient dosage was 1 : 15; the highest encapsulation efficiency was achieved when the amount of organic solvent (acetone) was 8 mL. The equation fitted to the model for the optimized prescription by the central composite design method is as follows: R 1 = − 166.93629 + 16.86478 A + 32.55582 B − 0.169750 AB − 0.482675 2 − 2.25797 B 2 R 2 = 0.9457 . The best prescription for the preparation of Chrysophanol-Pluronic F127 nanomicelles was obtained in the ratio of drug dosage to excipient dosage of 1 : 16.309 and the dosage of organic solvent was 6.595 mL. The prepared nanomicelles have a particle size of 152.8 nm and a potential of -23.9 mV. It was observed by transmission electron microscope that the prepared nanomicelles are uniform and spherical in appearance. The drug metabolism of Chrysophanol and nanomicelles in rabbits conforms to the two-compartment open model, and both of them show linear kinetics in the drug dose range. T 1 / 2 α was 0.31 ± 0.21 h and 0.47 ± 0.35 h, and T 1 / 2 β was 2.06 ± 1.14 h and 7.72 ± 2.04 h for Chrysophanol and Chrysophanol-Pluronic F127 nanomicelles, respectively. Conclusions. The adopted central composite design method can well optimize the prescription process of Chrysophanol-Pluronic F127 nanomicelles prepared by dialysis, and the method is simple and easy to be prepared in the laboratory. The prepared nanomicelles have uniform particle size and good zeta potential and appear as uniform black spherical shape under transmission electron microscopy. In vitro release studies showed that the Chrysophanol-Pluronic F127 nanomicelles released significantly better than Chrysophanol. The results of pharmacokinetics of Chrysophanol and Chrysophanol-Pluronic F127 nanomicelles in rabbits showed that the Chrysophanol-Pluronic F127 nanomicelles did not change the metabolic process of the drug in vivo but could stay in vivo for a longer period of time and exert longer effects. It is hoped that this study can provide a laboratory basis for the preparation of Chrysophanol-Pluronic F127 nanomicelles and a reference for further in vivo studies of Chrysophanol.

show abstract

Section: Single-factor Testmentioning

confidence: 99%

Study on Central Composite Design Method to Optimize the Preparation Process of Chrysophanol-Pluronic F127 Nanomicelles and Pharmacokinetics

Wang

Qiao³

et al. 2022

Journal of Nanomaterials

View full text Add to dashboard Cite

show abstract

Natural Variation in the Phenolic Composition of Rooibos and Changes During Production of Herbal Tea and Other Products

Joubert

Human

Beer

2023

Reference Series in Phytochemistry

View full text Add to dashboard Cite

Co-emulsified Alginate-Eudragit Nanoparticles: Potential Carriers for Localized and Time-defined Release of Tenofovir in the Female Genital Tract

Takalani,

Kumar,

Kondiah

et al. 2024

AAPS PharmSciTech

View full text Add to dashboard Cite

This research aimed to explore the possibilities of Eudragit S100 (ES100) and sodium alginate as carriers for tenofovir disoproxil fumarate (TDF) in the female genital tract. Alginate and alginate-ES100 nanoparticles were prepared using the ionic gelation and emulsion/gelation complexation method, respectively. The nanocarriers were tested using morphological, physicochemical, in vitro drug release, and cytotoxicity analyses. In SEM and TEM images, the presence of spherical and uniformly distributed nanoparticles was revealed. The FTIR spectrum showed that alginate and calcium chloride interacted due to ionic bonds linking divalent calcium ions and the -COO- of alginate groups. Alginate and ES100 interacted via the ester C=O amide stretching. The results obtained from XRD and DSC, on the other hand, revealed a favorable interaction between sodium alginate and ES100 polymers, as evidenced by the crystallization peaks observed. Under experimental design analysis and optimization, overall size distribution profiles ranged from 134.9 to 228.0 nm, while zeta potential results showed stable nanoparticles (−17.8 to −38.4 MV). The optimal formulation exhibited a maximum cumulative in vitro release of 72% (pH 4.2) up to 96 h. The cytotoxicity tests revealed the safety of TDF-loaded nanoparticles on vaginal epithelial cells at concentrations of 0.025 mg/mL, 0.5 mg/mL, and 1 mg/mL for 72 h. These results indicated that alginate-ES100 nanoparticles have the potential to preserve and sustain the release of the TDF drug in the FGT. The future goal is to develop a low-dose non-toxic microbicide that can be administered long term in the vagina to cater to both pregnant and non-pregnant HIV patients.

show abstract

Effect of electrospraying conditions on the properties of aspalathin‐Eudragit S100 nanoparticles and assessment of orogastrointestinal stability and membrane permeability

Cited by 3 publications

References 75 publications

Study on Central Composite Design Method to Optimize the Preparation Process of Chrysophanol-Pluronic F127 Nanomicelles and Pharmacokinetics

Study on Central Composite Design Method to Optimize the Preparation Process of Chrysophanol-Pluronic F127 Nanomicelles and Pharmacokinetics

Natural Variation in the Phenolic Composition of Rooibos and Changes During Production of Herbal Tea and Other Products

Co-emulsified Alginate-Eudragit Nanoparticles: Potential Carriers for Localized and Time-defined Release of Tenofovir in the Female Genital Tract

Contact Info

Product

Resources

About